The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PD-1 inhibitor (sintilimab) and fruquintinib plus SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a single-arm, phase 2 clinical trial.
 
Fei Ma
No Relationships to Disclose
 
Suxia Luo
No Relationships to Disclose
 
Bin Zhang
No Relationships to Disclose
 
Qi Ma
No Relationships to Disclose
 
Sheqing Ji
No Relationships to Disclose
 
Zhandong Zhang
No Relationships to Disclose
 
Yonglei Zhang
No Relationships to Disclose
 
Wei Yang
No Relationships to Disclose
 
Liangqun Peng
No Relationships to Disclose
 
Dandan Guo
No Relationships to Disclose
 
Jinjun Ren
No Relationships to Disclose
 
Yuan Zhang
No Relationships to Disclose
 
Yueyue Su
No Relationships to Disclose
 
Jing Li
No Relationships to Disclose
 
Wentao Liu
No Relationships to Disclose
 
Jinxi Huang
No Relationships to Disclose
 
Weiwei Yuan
No Relationships to Disclose